Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 6: AMD I Session

Date/Time: | Room:

Back to Previous

Title

Theme

08:00:00 P. Cardoso Portugal Clinical characteristics of the Charles Bonnet syndrome in patients with neovascular agerelated macular degeneration: The importance of early detection
08:06:00 S. Baillif France A realworld study to monitor wet agerelated macular degeneration patients treated with intravitreal aflibercept: 12month outcomes of RAINBOW stratified by treatment regimen
08:12:00 J. Monés Spain Complement C5 inhibition as a potential treatment for geographic atrophy secondary to dry agerelated macular degeneration
08:18:00 S. Doguizi Turkey Imaging characteristics of pigment epithelial detachments associated with neovascular age related macular degeneration and their response to intravitreal aflibercept therapy
08:24:00 E. van Dijk Netherlands The effect of corticosteroids on human choroidal endothelial cells: a model to study central serous chorioretinopathy
08:30:00 A. Fujita Japan Evaluation of polypoidal choroidal vasculopathy with Bscan flow images of swept source optical coherence tomography angiography
08:36:00 M. Figueroa Spain Treatment patterns of ranibizumab 0.5 mg over time in treatmentnaïve patients with neovascular agerelated macular degeneration: results from LUMINOUS™, a global realworld study
08:42:00 C. Tan Singapore Evaluation of indocyanine green angiographic features in symptomatic macular polypoidal choroidal vasculopathy over 24 months: results from the EVEREST II study
08:48:00 G. Staurenghi Italy Natural history of geographic atrophy secondary to age-related macular degeneration: Proxima A data from the 1year analysis of 100 patients
08:54:00 L. von der Emde Germany Darkadapted two color funduscontrolled perimetry and multimodal imaging to correlate structure and function in neovascular agerelated macular degeneneration
09:00:00 C. Awh United States LADDER trial of the port delivery system for ranibizumab: Preliminary study results
09:06:00 J. Hind United Kingdom 4 year “real world” outcomes of intravitreal Aflibercept for ARMD in Glasgow
09:12:00 N. Eter Germany PERSEUS 24month analysis: A prospective noninterventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in patients with wet agerelated macular degeneration
09:18:00 P. Prakash United Kingdom 3 years audit comparing the results of visual outcome, treatment frequency and number of visits using ranibizumab prn vs ranibizumab treat and extend vs aflibercept (as per license in UK) in patients with neovascular agerelated macular degeneration

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved